Immunic Analyst Price Targets - Benzinga

SPY757.12+0.19%QQQ692.74+0.33%BTC/USD78,399.00+1.24%DIA517.65+0.10%GLD356.15+0.10%TLT81.65−0.23%

Premium Services

Immunic Inc

IMUXNASDAQ

Trade with Public

Trade with Public

$7.51

-0.29-3.66%

Last update: Oct 30, 5:43 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Immunic Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunic (IMUX).

Price Target Range — 10 Quarters

Analyst Consensus — 13 Analysts

12Buy

1Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$60Upside to Avg. PT+686.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 23, 2026	Cantor Fitzgerald	Yanni Souroutzidis	Initiate	Overweight	—
Sep 10, 2026	Wedbush	Martin Fan	Maintained	Outperform	$45
Sep 10, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$22
Aug 17, 2026	Wedbush	Martin Fan	Initiate	Outperform	$45
May 22, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$40→$27
Apr 30, 2026	HC Wainwright & Co.	Matthew Caufield	PT Raise	Buy	$22→$5
Apr 17, 2026	Stifel	Paul Matteis	Initiate	Buy	$25
Apr 15, 2026	D. Boral Capital	Jason Kolbert	Downgrade	Buy→Hold	—
Mar 24, 2026	Guggenheim	Yatin Suneja	Initiate	Buy	$70
Mar 2, 2026	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$80→$50
Feb 13, 2026	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$80→$40
Feb 9, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$80
Jan 7, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$80
Nov 14, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$100→$80
Nov 13, 2025	D. Boral Capital	Jason Kolbert	PT Cut	Buy	$100→$80
Sep 29, 2025	Chardan Capital	Rudy Li	Initiate	Buy	$30
Sep 26, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$100
Sep 25, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$100
Aug 8, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$100
Jun 25, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$100

Analyst Ratings News

PRO
Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Immunic (NASDAQ:IMUX) with a Overweight rating.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Immunic, Maintains $45 Price Target

Wedbush analyst Martin Fan reiterates Immunic (NASDAQ:IMUX) with a Outperform and maintains $45 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Immunic (NASDAQ:IMUX) with a Buy and maintains $22 price target.

Benzinga Newsdesk

PRO
Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45

Wedbush analyst Martin Fan initiates coverage on Immunic (NASDAQ:IMUX) with a Outperform rating and announces Price Target of $45.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27

B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.

Benzinga Newsdesk

Amazon To Rally More Than 26%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings

Avi Kapoor